Award Number: DAMD17-98-1-8351

TITLE: Gene Regulation by Retinoid Receptors in Human Mammary Epithelial Cells

PRINCIPAL INVESTIGATOR: Victoria L. Seewaldt, M.D.
Jas Lang, Ph.D.

CONTRACTING ORGANIZATION: Ohio State University Research Foundation Columbus, Ohio 43210-1239

REPORT DATE: October 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Gene Regulation by Retinoid Receptors in Human Mammary Epithelial Cells

Victoria L. Seewaldt, M.D.
Jas Lang, Ph.D.

Ohio State University Research Foundation
Columbus, Ohio 43210-1239

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Retinoids are important mediators of normal growth and differentiation of epithelial cells and may play an important role in the chemoprevention of breast cancer. While normal mammary epithelial cells express retinoic acid receptors (RAR) a majority of breast cancers have selectively lost the expression of specific RAR isoforms. In order to investigate the molecular mechanisms by which loss of retinoic acid receptor function might promote the malignant transformation of mammary epithelial cells, we have inhibited retinoic acid receptor function in normal human mammary epithelial cells (HMECs). We observe that suppression of retinoic acid receptor function in HMECs results in dysregulated growth and inhibits structural differentiation. These observations lead us to hypothesize that retinoids and retinoic acid receptors may be important in regulating mammary epithelial cell growth and differentiation, and therefore, loss of retinoic acid receptor function might promote breast cancer carcinogenesis. The aim of this proposal is to identify and characterize genes activated or suppressed by loss of retinoic acid receptor function in human mammary cells. It is our hope that these studies will facilitate the understanding of normal mechanisms controlling growth and differentiation of HMECs and provide insight into how these normal processes may be altered in breast cancer.
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46. We are exempt because we are only using commercial cells with no identifiers.

In conducting research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.
IV INTRODUCTION

1. Title: Gene regulation by retinoid receptors in human mammary epithelial cells.

2. Principal Investigator: Victoria L. Seewaldt, M.D.
   Co-investigator: Jas Lang, Ph.D.

3. Key words: mammary carcinogenesis, retinoids, prevention, molecular biology, nutrition

4. Introduction:
Retinoids are important mediators of normal growth and differentiation of epithelial cells and may play an important role in the chemoprevention of breast cancer. While normal mammary epithelial cells express retinoic acid receptors (RAR) a majority of breast cancers have selectively lost the expression of specific RAR isoforms. This has lead to the hypothesis that loss of retinoic acid receptor function might be an important event in mammary carcinogenesis. In order to investigate the molecular mechanisms by which loss of retinoic acid receptor function might promote the malignant transformation of mammary epithelial cells, we have utilized a dominant-negative approach to inhibit retinoic acid receptor function in normal human mammary epithelial cells (HMECs). We observe in our in vitro system that suppression of retinoic acid receptor function in HMECs results in dysregulated growth and inhibits structural differentiation. These observations lead us to hypothesize that retinoids and retinoic acid receptors may be important in regulating mammary epithelial cell growth and differentiation, and therefore, loss of retinoic acid receptor function might promote breast cancer carcinogenesis. The aim of this proposal is to identify and characterize genes activated or suppressed by loss of retinoic acid receptor function in human mammary cells. We propose to investigate the differential expression of genes in normal HMECs relative to HMECs with suppressed retinoic acid receptor function exhibiting in vitro loss of structural differentiation. It is our hope that these studies will facilitate the understanding of normal mechanisms controlling growth and differentiation of HMECs and provide insight into how these normal processes may be altered in breast cancer.
V Body

In order to test the hypothesis that loss of retinoic acid receptor function might promote breast cancer carcinogenesis we suppressed normal retinoic acid receptor function in normal human mammary epithelial cells (HMECs) by retroviral-mediated expression of the dominant-negative retinoic acid receptor (DNRAR), LRARα403SN. This DNRAR is a truncated mutant RARα which acts as negative transcriptional regulator by simultaneously blocking all wild-type RAR isoforms (α, β, γ). The DNRAR dimerizes with retinoid receptors and binds retinoic acid response elements suggesting that the DNRAR acts by forming transcriptionally inactive heterodimers that compete for DNA binding with the natural retinoid receptor heterodimers. The advantage of this approach is that it is possible to disable the entire retinoic acid receptor pathway. We observed that inhibition of RAR function by a dominant-negative approach in HMECs results in dysregulated growth and inhibited the formation of a polarized ductal epithelium, suggesting that ATRA and RARs also play an important role in regulating proliferation and differentiation in mammary cells.

Technical Objectives:

Objective I: Isolation and characterization of retinoid-responsive genes activated or suppressed by retinoic acid receptors in normal human mammary epithelial cells. Formation of a polarized epithelial ductal structure is a characteristic of normal mammary cells and serves to distinguish normal from malignant mammary epithelial cells. We observe that inhibition of retinoic acid receptors in HMECs by a dominant-negative retinoic acid receptor (DNRAR) results in dysregulated growth and an inability of cells to form a normal polarized ductal epithelial structure when cultured in 3-dimensional extracellular matrix culture.

A) Isolation: We will employ the techniques of “differential display” and representational difference analysis of cDNA to isolate RA-regulated genes activated or inactivated by retinoic acid receptors in HMECs. RNA for differential analysis will be obtained from control HMECs (normal phenotype) and from HMECs whose normal retinoic acid receptor function is inhibited by a DNRAR (abnormal phenotype) grown in the presence of extracellular matrix.

B) Characterization: The function of candidate genes will be examined using sense and anti-sense sequences cloned into either retroviral or inducible expression vectors. Genes will be expressed in parental HMECs. Cells will be analyzed for growth characteristics and the ability to form a normal epithelial ductal structure in prepared extracellular matrix.

DATA:

Data for Objective IA: Isolation of genes regulated by retinoic acid receptor function in normal human mammary epithelial cells.

Preparation of RNA isolated from HMECs cultured in a prepared extracellular matrix:

HMECs with and without the DNRAR were plated on the nonadhesive substratum poly(2-hydroxyethyl methacrylate) (polyHEMA, Sigma). Poly-HEMA coated plates were prepared using an initial concentration of 0.25 mg/ml in 95% ethanol before drying. Approximately 1 X 10⁷ HMEC controls or HMEC whose normal receptor function is inhibited by a DNRAR were be plated per T-75 flask. Prepared extracellular matrix (Matrigel™) were diluted to 1% (vol/vol, approximately 200 µg of total protein per ml) in
standard medium was added to the culture as an overlay. Total mRNA was be isolated by the cesium chloride centrifugation method. Yield of total mRNA per 20 T-75 flasks was approximately 1.0 mg.

Identifying differences in mRNA expression by representational difference analysis of cDNA:

Poly(A+) mRNA was isolated from vector controls HMECs and HMECs whose retinoic acid receptor function is inhibited by a dominant-negative retinoic acid receptor (HMEC-DNRAR+). Approximately 200 µg total RNA was used to prepare poly(A+) mRNA using DYNAL beads (DYNAL) following the manufacture’s instructions. The yield was approximately 10 µg mRNA per sample. Differentially expressed cDNA was identified by PCR-Select Differential cDNA subtraction kit (Clontech). cDNA from HMEC-DNRAR+ cells was used as the tester and HMEC vector controls were used as the driver. A subtracted cDNA library was generated from each of the cDNA obtained from HMEC-DNRAR+ as well as HMEC controls. A secondary PCR amplification was performed using nested primers to reduce background PCR products and to enrich for differentially expressed sequences. The PCR products were directly sub-cloned into the pT-AdvTAgE PCR cloning kit. To ensure the identification of low-abundance sequences, the subtracted library was hybridized with forward- and reverse-subtracted cDNA probes. The forward-subtracted probe constituted subtracted cDNA library generated with HMEC-DNRAR+ and reverse-subtracted probe consisted of the HMEC vector control as a tested. Clones representing mRNAs that hybridized with only the forward-subtracted probe were considered truly differentially expressed. Isolated genes have been sequenced and compared against the GenBank and EMBL sequence databases for homology with known genes. Novel genes, especially those displaying classic transcription factor motifs, have receive priority in further characterization. Northern analysis using radiolabelled probes from candidate sequences are currently being performed to confirm differential expression in parental HMEC-DNRAR+ cells (and non-expression in HMEC controls). Full length cDNAs have been isolated from a commercial HMEC library (Clontech or Stratagene) for two genes and are we are currently in the process of isolating the remainder.

Summary of results to date:

96 clones initially screened
8 punative differentially expressed sequences
4 sequences sequenced
2 genes isolated

Sequences identified to date

<table>
<thead>
<tr>
<th>Clone Identification</th>
<th>E value</th>
<th>Isolated</th>
</tr>
</thead>
<tbody>
<tr>
<td>M17 Homo sapiens beta-subunit signal transduction gene</td>
<td>e-63</td>
<td>yes</td>
</tr>
<tr>
<td>P8 Homo sapiens protein tyrosine phosphatase</td>
<td>e-144</td>
<td>yes</td>
</tr>
<tr>
<td>M15 Homology with mus musculus proteinase-3</td>
<td>e-42</td>
<td>no</td>
</tr>
<tr>
<td>M23 Homo sapiens p58 receptor</td>
<td>5e-32</td>
<td>no</td>
</tr>
</tbody>
</table>
Next goals:

Methods for Objective IB: Characterization of genes activated or inactivated retinoic acid receptors in human mammary epithelial cells.

To determine if the isolated gene can inhibit structural differentiation of HMECs in vitro several strategies will be employed: 1) The cDNA will be cloned into the retroviral vector such as LXSN (containing a selectable neomycin resistance marker) and transduced into parental HMECs. This approach allows determination as to whether a candidate gene can inhibit structural differentiation of HMECs; 2) The LXSN retroviral vector will be used to express anti-sense cDNA in the same target cells by reversing the orientation of the cDNA inserts; 3) An expression vector with inducible promoters such as the tetracycline-regulated tTA/tetO (35) system may be used to achieve regulated expression in target cells. HMECs expressing the isolated gene or anti-sense will be grown in a prepared extracellular matrix as described above. Cells will then be assessed by light microscopy and by electron microscopy for the ability of the target gene to alter the formation of a acinus-like structure in vitro and to suppress growth inhibition by the presence of extracellular matrix.

VI Summary:

We have utilized a unique in vitro system to isolate genes regulated by retinoic acid receptors in normal human mammary epithelial cells. We have utilized the technique of RDA to isolate differentially expressed genes in our model system. We have identified to date 8 potentially differentially expressed sequences, have identified 4 genes, and have isolated 2 genes. The two genes that have been isolated are of particular interest because they are signal transduction genes and are potentially We are in the process of confirming that these identified sequences are differentially expressed in our model system. Two genes have been isolated. Our next goals are to:

1) Sequencing of the remaining 4 clones.
2) Finalize the differential expression of our 4 sequenced genes by PCR and Northern Analysis.
3) Isolate remaining genes.
4) Determine if our isolated genes can inhibit structural differentiation of HMECs in vitro.
Request for Change of Co-Investigator

Previously, the grant had been budgeted for Dr. Schickwann Tsai at Mount Sinai Hospital to be our Co-Investigator. Funds were budgeted as a subcontract because Dr. Tsai and myself were at different institutions. We have requested that Dr. Jas Lang at Ohio State University be our new Co-Investigator. For this reason, funds to our Co-Investigator are now to be paid as funds within Ohio State and not as a “Sub-Contract”.
# REPORT OF INVENTIONS AND SUBCONTRACTS
(Pursuant to "Patent Rights" Contract Clause) (See Instructions on Reverse Side.)

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0292), Washington, DC 20503.

## 1. NAME OF CONTRACTOR/SUBCONTRACTOR
The Ohio State University Research Foundation

<table>
<thead>
<tr>
<th>c. CONTRACT NUMBER</th>
<th>b. ADDRESS (Include ZIP Code)</th>
<th>a. NAME OF CONTRACTOR/SUBCONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAMD17-98-1-8351</td>
<td>160 Kenny Rod Columbus, OH 43210-1063</td>
<td>The Ohio State University Research Foundation</td>
</tr>
</tbody>
</table>

## 2. NAME OF GOVERNMENT PRINCIPAL CONTRACTOR
US Army Medical Research Acquisition Activity

<table>
<thead>
<tr>
<th>c. CONTRACT NUMBER</th>
<th>b. ADDRESS (Include ZIP Code)</th>
<th>a. NAME OF GOVERNMENT PRINCIPAL CONTRACTOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAMD17-98-1-8351</td>
<td>MCML-AAA-B 820 Chandler St. Fort Detrick, MD 21702-5014</td>
<td>US Army Medical Research Acquisition Activity</td>
</tr>
</tbody>
</table>

## 3. TYPE OF REPORT (Ex one)
X ( ) INTERIM ( ) FINAL

## 4. REPORTING PERIOD (Fiscal Years)
( ) FROM ( ) TO
980925 990924

---

### SECTION I - SUBJECT INVENTIONS

#### a. NAME(S) OF INVENTOR(S) (Last, First, MI)

<table>
<thead>
<tr>
<th>b. TITLE OF INVENTION(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NONE</td>
</tr>
</tbody>
</table>

#### 1. EMPLOYER OF INVENTOR(S) NOT EMPLOYED BY CONTRACTOR/SUBCONTRACTOR

<table>
<thead>
<tr>
<th>(a) Name of Inventor (Last, First, MI)</th>
<th>(b) Name of Employer</th>
<th>(c) Address of Employer (Include ZIP Code)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### g. ELECTED FOREIGN COUNTRIES IN WHICH A PATENT APPLICATION WILL BE FILED

( ) Yes ( ) No

---

### SECTION II - SUBCONTRACTS (Containing a "Patent Rights" clause)

#### 6. SUBCONTRACTS AWARDED BY CONTRACTOR/SUBCONTRACTOR (If "none," to state)

<table>
<thead>
<tr>
<th>a. NAME OF SUBCONTRACTOR(S)</th>
<th>b. ADDRESS (Include ZIP Code)</th>
<th>c. SUBCONTRACT NO(S)</th>
<th>d. DFAR &quot;PATENT RIGHTS&quot;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mount Sinai School of Medicine</td>
<td>1 Gustave L. Levy Place New York, NY 10029</td>
<td>P.O. 822775</td>
<td></td>
</tr>
</tbody>
</table>

#### e. DESCRIPTION OF WORK TO BE PERFORMED UNDER SUBCONTRACT(S)

Research

<table>
<thead>
<tr>
<th>f. SUBCONTRACT DATES (FYMMDD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Award (2) Estimated Completion</td>
</tr>
<tr>
<td>980925 990924</td>
</tr>
</tbody>
</table>

---

### SECTION III - CERTIFICATION

#### 7. CERTIFICATION OF REPORT BY CONTRACTOR/SUBCONTRACTOR

( ) Required if a ( ) Small Business or ( ) Non-Profit organization. ( ) (appropriate box)

<table>
<thead>
<tr>
<th>a. NAME OF AUTHORIZED CONTRACTOR/SUBCONTRACTOR OFFICIAL (Last, First, MI)</th>
<th>c. I certify that the reporting party has procedures for prompt identification and timely disclosure of &quot;Subject Inventions,&quot; that such procedures have been followed and that all &quot;Subject Inventions&quot; have been reported.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marta L. Morris</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>b. TITLE</th>
<th>d. SIGNATURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interim Director Health Sciences Office</td>
<td>Marta L. Morris</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>e. DATE SIGNED</th>
</tr>
</thead>
<tbody>
<tr>
<td>990924</td>
</tr>
</tbody>
</table>

DD Form 882, OCT 89

Previous editions are obsolete.